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Abstract

Antibiotics are of the utmost importance in the fight against pathogenic bacteria,
however, in recent years there has been a continual increase in the development of
antibiotic resistance among bacteria. As a result it has become essential to develop
new technologies to combat these pathogens. One such technology is the application
of phage lysins as antimicrobial agents against pathogenic infections. A promising
phage lysin is LysK, a 495 amino-acid protein derived from Staphylococcal Phage K.
LysK can lyse a wide range of staphylococcal species including MRSA. It is also
capable of killing both live and dead cells increasing its potential as an effective
therapeutic

antimicrobial.

Bacteriocins and other antimicrobial peptides have also attracted attention as possible
antimicrobial agents. These compounds may be used in isolation or in combination
with currently used antimicrobial compounds to exert their toxic effects on the
pathogenic cell One such compound is Enterolysin A (EntL),a 343aa lytic enzyme
produced by Enterococcus faecalis DPC5280. EntL is a metallopetidase which can
kill a range of Gram positive bacteria including Lactococci sp.
In the current study, the phage lysin LysK and its truncated 165aa derivative
Cl,

which

consists

of

the

catalytic

cysteine-

and

histidine-dependent

amidohydrolase/peptidase (CHAP) domain, were purified by ion exchange
chromatography. These were further processed via size exclusion chromatography
which ensured a high degree of purification. The native EntL protein, which encodes
the bacteriocin Enterolysin A, was purified by immobilized metal affinity
chromatography (IMAC).
Secondary structure analysis was performed on all three proteins (LysK, Cl

and EntL) using both experimental and predictive techniques. Whilst the results were
not in complete agreement they did both suggest each protein involved was composed
predominantly of P-sheet and coil consisting in the least amount of a-helix. Thermal
denaturation experiments were performed using circular dichroism. LysK was the
only protein which showed refolding capabilities suggesting the amidase and cell wall
binding domains play a role in protein refolding capabilities. The ability of a protein
to refold is a property which can increase its shelf life which is beneficial for
manufacturing and storage of an antimicrobial agent. Crystallization parameters were
detennined for the CHAP domain. 2M Am sulphate, 2% PEG 400, Cacodylate pH 7.5
gave long needle like crystals which took approximately a month to grow at room
temperature

Chapter I

Literature Review

Phage- and Bacteria-Derived Proteins as Alternatives to Antibiotics

1.1

Introduction
Since their discovery over 60 years ago, antimicrobial agents such as

antibiotics have been critical in the fight against infectious diseases caused by
bacteria and other microbes. In addition to improvements in sanitation, housing,
nutrition and the introduction of global immunisation programmes, antimicrobial
chemotherapy has been paramount in the reduction in the numbers of deaths from
diseases that were previously widespread, untreatable and often fatal and has been the
leading cause for the dramatic rise of average life expectancy in the 20^^ century
(Source; WHO). However, the increasing use and misuse of antibiotics along with the
remarkable ability of bacteria to develop ways of resisting the action of these agents
has resulted in widespread antibiotic resistance among the microbial population. The
emergence and spread of bacteria resistant to ‘first-line’ drugs has substantially
increased the threat posed by infectious diseases. It is no surprise that the bacteria
which cause significant human disease are those in which emerging resistance is most
evident. Most pathogenic strains have become antibiotic resistant and some have
developed multi-drug resistance, becoming resistant to many antibiotics and
chemotherapeutic agents. These include many Gram-positive pathogens such
penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci,
methicillin-resistant Staphylococcus aureus, multi drug-resistant Salmonella and
multidrug-resistant Mycobacterium tuberculosis (Source: WHO).
In light of the prevalence of these multidrug-resistant strains, the need for
effective new measures to control such infections has never been greater. Such
measures include increased control of the use of existing antibiotics, improvements in
8

hygiene in hospitals, and the renewal of efforts to seek alternative antibacterial agents
effective against pathogenic bacteria resistant to current antibiotics (Flaherty 2009
).One possibility is the use of phage- and bacteria-derived products for disease
therapy. Prior to the discovery and widespread use of antibiotics, it was suggested
that bacterial infections could be prevented and/or treated by the administration of
bacteriophages (phages) (Sulakvelidze, Alavidze et al. 2001). It has since been
reported that the appropriate administration of living phage can be used to treat
potentially lethal infections caused by Gram-negative bacteria, such as Escherichia
coli. Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae.
Vibrio vulnificus, and Salmonella spp., and Gram-positive bacteria, such as
Enterococcus faeciurn and Staphylococcus aureus (Matsuzaki, Rashel et al. 2005).
Phage lysins have also been studied and utilized in their own right as potential
therapeutics for the treatment of bacterial infections. Indeed, the past decade has seen
a considerable amount of research worldwide focused on the engineering of phages as
antibacterial agents in a wide range of applications. Bacteriocins and other
antimicrobial peptides have also attracted attention as potential substitutes for, or as
additions to, currently used antimicrobial compounds.

1.2

Antibiotic Resistance in Bacteria

Widespread use of antimicrobials in a clinical setting has been associated with the
emergence of multidrug-resistant microorganisms. Antibiotics were first discovered,
in the form of penicillin, by Alexander Fleming in 1928. His work eventually led to
the large-scale production of penicillin from the mould Penicillium notatum in the
1940s. As early as the late 1940s, resistant strains of bacteria began to appear. The
discovery of penicillin was followed by the discovery and commercial production of
many other antibiotics and their use has had an enormous impact on disease-causing
9

bacteria. The majority of these pathogenic bacteria have become antibiotic resistant.
Currently, it is estimated that more than 70% of the bacteria that cause hospitalacquired infections are resistant to at least one of the antibiotics used to treat them
(Source: NIAID). Indeed, some pathogens have become resistant to practically all of
the commonly available agents, a phenomenon known as multidrug resistance
(Nikaido 2009). A notorious case is the methicillin-resistant Staphylococcus aureus
(MRSA), discussed below. This organism is resistant not only to methicillin but
usually also to aminoglycosides, macrolides, tetracycline, chloramphenicol, and
lincosamides. Antibiotic resistance continues to expand for a multitude of reasons,
including over-prescription of antibiotics by physicians, non-completion of prescribed
antibiotic treatments by patients, use of antibiotics in animals as growth enhancers
(primarily by the food industry), increased international travel and poor hospital
hygiene.

1.2.1

Methicillin-resistant and Vancomycin-resistant Staphylococcus aureus
Some pathogens have become resistant to almost all of the commonly available

antibiotics. One example is MRSA, which is not only resistant to methicillin, but also
to aminoglycosides, macrolides, tetracycline, chloramphenicol, and lincosamides.
(Perreten, Kadlec et al. 2010). MRSA infection first emerged in the UK in 1961; by
the 1990s, MRSA was considered to be endemic in most areas of the world.(Wang,
Cao et al. 2009). Since their emergence, MRSA strains have generally been
transmitted by nosocomial means, i.e. acquired by persons who have had frequent or
recent contact with hospitals or healthcare facilities (such as nursing homes or
dialysis centres) within the previous year, or have recently undergone an invasive
medical procedure, or are immuno-compromised.(Salmenlinna, Lyytikainen et al.
2002).
10

However, due to changing trends in epidemiology, MRSA has become a
problem in the community. Community outbreaks have been reported in sports teams,
child care attendees, prison inmates, and diverse populations where habitation is
relatively concentrated.(Evans 2008). Frequently, community-acquired MRSA (or
CA-MRSA) isolates are associated with skin and soft-tissue diseases (Ribeiro, Dias et
al. 2005) however the pathogen has been known to cause life threatening infections
such as osteomyelitis, necrotizing pneumonia and fatal sepsis. CA-MRSA was
brought to world prominence in 1999 when the deaths of four young children resulted
from necrotizing pneumoniae caused by MRSA. The cases were alarming as none of
the children had predisposing factors for MRSA. (Said-Salim, Mathema et al. 2003).
MRSA was first reported in Irish hospitals in 1971, 10 years after the initial
report of MRSA in England. (Shore, Rossney et al. 2005) Between 1989 and 1998,
the number of patients carrying MRSA in one Dublin hospital increased
fourfold.(Rossney and Keane 2002). In Ireland during 2002, 416 of 998 (42%) S.
aureus isolates from human patients with bacteraemia were resistant to methicillin,
placing Ireland fourth highest of 27 European countries submitting data to the
European Antimicrobial Resistance Surveillance System (EARSS)(0'Mahony,
Abbott et al. 2005). The most recent EARSS study carried out in 2005 shows Ireland
has moved to becoming the country with the third highest prevalence of MRSA
where 45% (Fig: 1.4) of S. aureus isolates were resistant to methicillin.
All methicillin-resistant S. aureus (MRSA) isolates tested so far harboured the
mobile element staphylococcal cassette chromosome mec (SCCmec). The SCCwec
carries the mec gene complex, encoding methicillin resistance, and the ccr gene
complex, encoding recombinases. This accessory element can display different
combinations of mec gene and ccr gene complexes. As determined on the basis of this

11

diversity, five types of SCCwec and their variants have been reported previously
.(Ribeiro, Dias et al. 2005)
PBP2a encoded by the mecA gene of the staphylococcal cassette chromosome is an
altered penicillin binding protein which is responsible for the resistance to methicillin
in MRSA.
Vancomycin is the preferred antibiotic for treatment of MRSA and the newly
emerged CA-MRSA. The term VRSA, or vancomycin-resistant S. aureus, suggests
the failure of vancomycin to eradicate S. aureus infections even when administered in
appropriate doses for what should be adequate periods of time.(Tenover 1999). The
first two clinical isolates of vancomycin-resistant S. aureus (VRSA) were recovered
from patients in Michigan and Pennsylvania in June and September of 2002,
respectively (Clark, Weigel et al. 2005). Strains of vancomycin-intermediate S.
aureus (VISA) with vancomycin MIC of 8 pg/ml have been reported from Japan, the
United States, France, United Kingdom and Germany. Most of these isolates appear
to have developed from pre-existing MRSA infections.(Tiwari and Sen 2006).
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Figure 1.3 Number of MRS A cases per 1,000,000 of population. (Source. EARSS).

1.2.2

Vancomycin-resistant enterococci
Enterococci are opportunistic pathogens which are normally present in the gut

flora but when the host immunity is low they will cause infection (Catalano, Hahn ef
al. 2000) Vancomycin-resistant enterococci (VRE) were first identified as hospitalassociated pathogens in Europe during the mid-1980s and have rapidly disseminated
worldwide. (Tacconelli and Cataldo 2008).

The emergence of VRE has become a

serious problem and an established nosocomial pathogen contributing significantly to
hospital-acquired infections worldwide, since it was isolated in the late 1980s.
Vancomycin cannot be used to treat the increasing number of VRE infections.(Wang,
Cao et al. 2009).

In 2008, the European Antimicrobial Resistance Surveillance System
(EARSS), a network of national surveillance systems, reported vancomycin resistance
rates among enterococci which ranged from <1% in Norway, Finland, France and
Bulgaria to 23.7% in Portugal. Countries showing the highest reported vancomycin
13

resistance rates among enterococci were Ireland, the United Kingdom and Greece.
According to EARSS in 2008 (Fig 1.4) Ireland had the highest proportion of
vancomycin-resistant E.faecium in Europe at 34.6% resistant isolates. This has risen
from 11.1% of vancomycin-resistant E. faecium in 2002. The figures above from
EARSS showing the rise in VRE isolates in just 6 years suggests that VRE is
becoming an increasing problem in Ireland.

Fig 1.4: Proportion of Vancomycin resistant E.faecium isolates in participating countries in 2008.
EARSS

14

1.3

Alternatives to antibiotics - bacteriophage therapy

One possible option to combat antibiotic resistance within the microbial
population is the use of bacteriophage as antimicrobial agents. Lytic phage kill
bacteria via mechanisms that differ from those of antibiotics, a concept desired for all
new antibacterial agents. The use of phages to treat bacterial infections in animals and
humans is an old idea (Sulakvelidze et al., 2001). In Eastern Europe and the fonner
Soviet Union, phage therapy has been used successfully to treat bacterial dysentery
(Babalova, Katsitadze et al.

1968; Tolkacheva, Abakumov et al.

1989),

staphylococcal lung infections (Ioseliani, Meladze et al. 1980), surgical wound
infections (Zhukov-Verezhnikov, Peremitina et al. 1978), among others. Phage
therapy was exploited for both diarrhoeal disease and the treatment of traumatic
infections during and after World War II (Sulakvelidze 2005). During the 1920s and
1930s, therapeutic phage applications spread rapidly in response to a desperate need
for treatment of bacterial infections in Western Europe and the USA. However, with
the development of antibiotics for the treatment of infections in the early 1940s and
their concomitant widespread use, early clinical trials were abandoned in the West.
Phage therapy is still practised routinely in the former Soviet Union as an alternative,
combinatory, and complimentary form of treatment in conjunction with, or in lieu of,
antibiotics. Several studies have shown that carefully selected phage preparations
may be as efficacious as antibiotics in the treatment of certain bacterial diseases
(Meladze, Mebuke et al. 1982; Kochetkova, Mamontov et al. 1989; Sakandelidze
1991). Recently, there has been a renewed interest in bacteriophage therapy in
Western Europe and in the USA as a viable alternative to treat the many emerging
drug-resistant pathogenic bacteria.
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There are several potential advantages of using phage therapy over antibiotics
such as high specificity to the target organism and a lack of toxicity associated with
the phage (Alisky, Iczkowski et al. 1998). Phages are also self-replicating and selflimiting, i.e. they multiply only as long as the infection is present (Mathur, Vidhani et
al. 2003). Other advantages include the ability to rapidly modify phage to combat the
emergence of newly arising bacterial threats, and their history of safe use, as
emphasised by their extensive use in Eastern Europe (Sulakvelidze 2005). However,
despite phage therapy’s long history in Eastern Europe and the former Soviet Union,
therapeutic preparations would have to undergo a rigorous approval process by
various regulatory agencies before they could be commercialised and used to treat
humans in the western world. The efficacy of lytic phages in a clinical setting is still a
controversial issue. Specific problems associated with using phages as therapeutic
phages in humans include the failure to establish rigorous proof of efficacy and the
specific mode of action responsible for the therapeutic effect. Also questions
regarding the distribution of phages in the body, the clearance of phages by the
immune system through the development of phage-neutralizing antibodies,
development of bacterial resistance to bacteriophage and the potential for phage
conversion of bacterial targets have yet to be adequately addressed.

Some recent studies have demonstrated the potential efficacy of phages against
antibiotic-resistant pathogens.
Cheng et al., 2005 have successfully developed a phage which lyses Group B
Streptococci which is responsible for neonatal meningitis and sepsis. The PlyGBS
lysin has successfully lysed all GBS serotypes in vitro and in vivo has been found to
significantly reduce bacterial colonization in both the vagina and oropharynx in

16

mouse models. (Cheng, Nelson et al. 2005). This study shows promise in the future
treatm.ent of Group B streptococcus neonatal meningitis and sepsis.
Uchiyama et al, 2010 report a lysin MV-L encoded by the S.aureus
bacteriophage phi MRll. This lysin rapidly and totally lysed cells of a number of
S.aureus strains including MRS A and VRSA. MV-L also successfully lysed bacteria
that had been intraperitonealy inoculated into the nares of mice. The lysin also saved
the mice against MRS A septic death indicating that MV-L may be a powerful
therapeutic against muliti drug resistant S.aureus. (Rashel, Uchiyama et al. 2007)
A huge breakthrough in veterinary medicine has been recently made by
Hawkins et al., 2010 10 dogs with chronic Pseudomonas aeruginosa otitis were
administered directly into the ear canal with a bacteriophage preparation containing 6
different phage strains. After a period of 48 hours the count of P. aeruginosa had
fallen an average of 67% and the bacteriophage counts had increased an average of
99.1 fold. No adverse effects were detected in the study. (Hawkins, Harper et al.
2010)

Another phage, CSV-31, has been successfully applied to multidrug-resistant
(MDR) P. aeruginosa infection in mice (Vinodkumar, Kalsurmath et al. 2008) .
Septicemic mice were administered with the phage 45 minutes after bacterial
challenge which resulted in 100% rescue rate of the animals. In another study,
bacteriophage K01, derived from an induced bum wound infection by Klebsiella
pneumoniae, was found by Malik et al., 2009 to be effective in the treatment of post
burn infections caused by K. pneumoniae. Mice infected with K. pneumoniae were
subcutaneously and intraperotoneally treated with phage K01 30 mins and 6 hours
post infection. Significant reduction in bacterial numbers was observed 3 hours post
treatment with phage K01 via the subcutaneous route and 6 hours via the
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intraperitoneal route indicating that phage K01 is effective is treating burn wound
mice infected with phage K01. (Malik and Chhibber 2009)
Companies such as “BigDNA” in the UK are coming up with even more
novel uses for phages by manufacturing phage vaccines. They are engineering phages
to contain DNA vaccines which can be administered orally to vaccinate the host
who’s own cells take up the DNA vaccine.
The possibilities for the future of phage, phage lysins and bacteriocins are
endless with an abundance of impressive applications.

1.4.

Phage- derived proteins as antimicrobials
Bacteriophage endolysins have in recent years attracted attention as potential

substitutes for, or as additions to, currently used antimicrobial compounds. Lysins
have the advantage of specifically targeting peptidoglycan bonds within the cell wall.
Phage endolysins are proteins that usually contain an amino-temiinal domain
possessing enzymatic activity that involves hydrolysis of a peptidoglycan bond and a
carboxy-terminal domain that confers binding specificity to a carbohydrate epitope in
the bacterial cell wall (Rotem, Radzishevsky et al. 2006). Lysins are produced during
the lytic cycle of bacteriophages. With few exceptions, lysins do not have signal
sequences, so they are not translocated through the cytoplasmic membrane to attack
their substrate in the peptidoglycan; this movement is controlled by a second phage
gene product in the lytic system, the hoi in. During phage development in the infected
bacterium, lysin accumulates in the cytoplasm in anticipation of phage maturation. At
a genetically specified time, holin molecules are inserted in the cytoplasmic
membrane forming patches, ultimately resulting in generalized membrane disruption ,
allowing the cytoplasmic lysin to access the peptidoglycan, thereby causing cell lysis
18

and the release of progeny phage (Fischetti 2008). What makes phage lysins attractive
as therapeutic agents is that they are also capable of iysis from without’, meaning
that they are capable of digesting peptidoglycan even when externally applied. This
particularly occurs in Gram-positive bacteria (Nelson, Loomis et al. 2001). Phage
lysins have attracted considerable interest as novel antimicrobials against Gram
positive bacteria and have been used to control a wide range of pathogens such as
group A streptococci , Streptococcus pneumoniae , Bacillus anthracis , and
Enterococcus faecalis (O'Flaherty, Coffey et al. 2005). However, in Gram-negative
bacteria, the peptidoglycan layer is surrounded by the outer membrane and hence
impermeable to macromolecules which renders them resistant to endolysin activity. It
has been reported that some endolysins are capable of killing Gram negative bacteria
by means of their C-terminal membrane active peptide sequence. This has only been
found in two endolysins to date but it is possible that it is present in others. (Alisky,
Iczkowski et al. 1998). As potential antibacterials, endolysins possess several
important features, for instance, a novel mode of action, a narrow antibacterial
spectrum, activity against bacteria regardless of their antibiotic sensitivity, and a low
probability of developing resistance.(Borysowski, Weber-Dabrowska et al. 2006).
Table 1 shows a list of lysins currently being researched for potential use as
antimicrobials, some of which will be dealt with in further detail at a later point.
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Table 1.1 Phage endolysins with demonstrated effect against pathogens.

Endolysin

Host phage

Target pathogens

LysK

Staphylococcal Phage K

S. aureus (MRS A)

PlyC

Streptococcal Phage C1

S,pyogenes, S.uberis, S.equi, Grou]
B streptococci

PlyGBS

Cpl-1,PAL

Streptococcal Phage

Group D streptococci, Group L

NCTC11261

streptococci, S.salivarius

Pneumococcal phage dpi

S. pneumonaie, E.faecalis, E.
faecium, S.pyogenes, Groups B, C,
E, F, L, N streptococci

PlyV12

S.uberis, S. gordinii, S.

Enterococcal phage 1

mtermedius, S. parasanguisi,
S. aureus.
ClyS

Pneumococcal Phage cp-1

S.aureus (MRSA, VISA)

PlyB

Bacillus anthracis Phage BcPI

B. anthracis, B. cereus,
B. thuringiensis, B. megaterium

PlyG

Bacillus anthracis Gamma phage

B. anthracis

lysH5

S. aureus bacteriophage PhiH5

bovine and human S. aureus, and
human S. epidermidis strains

MV-L

S. aureus bacteriophage phi MRl 1

^.aureus (MRSA, VISA)

phill -

S. aureus bacteriophage phi 11

staphylococcal mastitis pathogens,

endolysin

S.aureus and coagulasenegative staphylococci
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Figure 1.6 Lysins target the cell wall

The majority of phage lysins studied to date are modular in structure, composed
of at least two distinctly separate functional domains: a C-terminal cell-wall binding
domain, which directs the enzyme to its target, and an N-terminal catalytic domain.
The catalytic domain can comprise one or more of the following types of
peptidoglycan

hydrolases:

endopeptidases,

muramidases

(lysozyme),

N-

acetylmuramoyl-L-alanine amidases and glucosamidases. Peptidoglycan is made up
of the repeat polymer of the amino sugars 7V-acetylglucosamine and A^-acetylmuramic
acid (MurNAc), linked together by 6-1,4 glycosidic bonds, and tetrapeptide side
chains attached to the lactyl group of the muramic acid by amide bonds (Borysowski,
Weber-Dabrowska et al. 2006). Adjacent tetrapeptides may be cross-linked by an
21
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interpeptide bond (in Gram-negative bacteria) or by an interpeptide bridge (in Gram
positive bacteria). The cell wall in Gram-positive bacteria consists of several layers of
peptidoglycan and is much thicker (15-80nm) than the cell wall of Gram negative
bacteria (lOnm) which is composed of a single layer of peptidoglycan surrounded by
the outer membrane (Borysowski, Weber-Dabrowska et al. 2006). Lysins target the
integrity of the cell wall and attack one of the four major bonds in petidoglycan. Each
of the catalytic domains breaks down specific bonds within the peptidoglycan.
A very promising and interesting approach in the treatment of pathogenic
disease is based on using purified lysins to kill the target selected bacteria whilst
having only a minimal effect on commensal bacteria. This is a huge advantage over
conventional antibiotics. (Rotem, Radzishevsky et al. 2006) The bacterial host range
of phage is usually narrower than that found in antibiotics that have been selected for
clinical applications. Having a limited host range can be advantageous given that
many antibiotics are of a broad range and along with killing off the target bug can
also upset the normal gastrointestinal flora which can result in opportunistic
secondary infections by organisms such as Clostridium difficile (Posani 2004). It is
usual that a lysin would only kill the species or subspecies of bacteria from which
they were derived from, for example, LysK produced from a staphylococcal phage
can kill many Staphylococcus species including MRSA. (O'Flaherty, Coffey et al.
2005). A lysin from a group C streptococcal phage (PlyC) can kill group C
streptococci, as well as groups A and E streptococci, the bovine pathogen S. uheris
and the horse pathogen, S. equi, but essentially has no effect on streptococci normally
found in the oral cavity of humans and other Gram-positive bacteria. (Fischetti 2008).
A number of studies have examined the feasibility of using phage lysins for
therapeutic purposes. (Loeffler, Djurkovic et al. 2003) reported the use of CpL-1
lysin from Pneumococcal phage dpi as an intravenous therapy in a mouse model for
22

pneumonoccal bacteremia. Mice were colonized with a penicillin susceptible S.
pneumonia serotype 14 strain and were left for 10 hours before being treated with a
single dose CpL-1 Lysin. The numbers of colonising bacteria were reduced by several
logs within 15 minutes from a median logio of 4.70 CFU/ml to a logio 2.0 CFU/ml. It
was observed that, similar to other proteins which have been delivered to animals
intravenously, CpL-1 has a half life of 15-20 minutes. In mice infected with advanced
bacteraemia, treatment with two doses of CpL-1 significantly increased the survival
time, though the infected animals did eventually succumb to infection. The relatively
small half life of the lysin in blood contributed to the result. However, this short halflife is not unusual for foreign proteins and is similar to that found for streptokinase, a
thrombolytic enzyme used for treatment of acute myocardial infarction.(Loeffler,
Djurkovic et al. 2003) After administration of a single bolus of the lysin, the titres in
the blood of animals dropped by 99% and stayed there for at least 2 hours. These
results are indicative that phage lysins may have the ability to eliminate pneumococci
or lessen the impact of the infection to a level at which the host immune system is
able to take over, if the enzymes are given by constant intravenous infusion for an
established period.(Loeffler, Djurkovic et al. 2003).

1.4.1. LysK

LysK, one of the lysins used in this study, is derived from the staphylococcal
phage K and found by Flaherty et al. 2005 to inhibit a number of staphylococcal
species isolated from both bovine and human infection sources, including the ‘super
bug’ methicillin-resistant S. aureus. Phage K is a polyvalent phage of the Myoviridae
family which is active against a wide range of staphylococci. LysK is a 495 aminoacid protein which has a broad spectrum of activity against different staphylococci,
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including MRSA. Most lysins will kill autoclaved dead cells so a unique property of
LysK is that it has the potential to be an antimicrobial against MRSA as it can lyse
live cells. (Horgan, O'Flynn et al. 2009)
LysK has a modular structure which consists of a C-terminal SH3b cell wall
binding domain, an N-terminal catalytic domain CHAP (cysteine- and histidinedependent amidohydrolase/peptidase) and another central amidase 2 domain also with
caltal3^ic activity (A-acetylmuramoyl-L-alanine amidase) (Fig. 1.7).

LysK
Cell binding domain

Catalytic domains

CHAP

Amidase2

SH3b

Figure 1.7 LysK domains. CHAP (cysteine- and histidine-dependent amidohydrolase/peptidase),
amidase 2 (/V-acetylmuramoyl-L-alanine amidase), SH3b (cell wall binding).

A series of deletion studies of the LysK protein , performed by Horgan et al,
2009 (Fig. 1.8), revealed that, unlike the previously characterised staphylococcal
lysin phi 11, the amidase-2 and SH3b domains were not required for lytic activity of
LysK. A 162 amino acid derivative containing only the CHAP domain displayed lytic
activity similar to that of the intact LysK protein. Importantly, the 162 amino acid
truncated LysK retained the broad spectrum of activity of the native enzyme in that it
was capable of lysing a wide range of staphylococci, including MRSA. A smaller
protein, such as CHAP, could be desirable if a phage endolysin is to be used as a
therapeutic tool. Intact endolysins are large proteins which can elicit a humoral
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immune response particularly when they are administered intravenously. Therefore,
the construction of single domain proteins could be favoured since it may decrease
the likelihood of a significant immunogenic response. (Horgan, O'Flynn et al. 2009).
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very faint zone of clearing, (taken from Horgan et al., 2009).

Bacteria-derived proteins as antimicrobials - Bacteriocins
Bacteriocins are antimicrobial peptides produced by bacteria which can have a

narrow or broad host range. (Cotter, Hill et al. 2005). Bacteriocins provide a defence
mechanism for the producer strain as they can kill other bacteria, because of this they
are being used as food preservatives (O'Sullivan, Ross et al. 2002) and as a possible
alternative to antibiotics (Brook 2005), (Gillor, Nigro et al. 2005). There are 5 classes
of bacteriocin. Class I are small, heat-stable peptides containing (methyl) lanthionine
residues which may form intramolecular thioether rings (Moll, Konings et al. 1999).
Class II are similar to Class I as they are also small and heat stable however they
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differ in that they do not undergo posttranslational modification and tend to have a
narrower spectrum of inhibition than Class I peptides. (De Kwaadsteniet, Fraser et al.
2006) . Class III are large heat-labile bacteriocins which have been reported to show
antimicrobial properties (de Jong, van Hijum et al. 2006), (Nigutova, Morovsky et al.
2007) . Class 4 are the complex bacteriocins carrying lipid or carbohydrate moieties
and finally class 5 are circular bacteriocins (de Jong, van Hijum et al. 2006)

1.5.1

Enterolysin A (EntL)
EntL is a lytic enzyme produced by Enterococcus faecalis strain DPC5280

(Hickey, Ross et al. 2004). EntL was purified and sequenced by Nilsen et al, 2003
who found the primary structure to be translated as a 343 preprotein with a secdependant signal peptide of 27 amino acids, followed by a sequence corresponding to
the N-terminal of the purified protein. (Nilsen, Nes et al. 2003) EntL kills a wide
range of Gram-positive bacteria including enterococci, pediococci, lactococci and
lactobacilli and is a class 3 bacteriocin. EntL is a member of the peptidase family
M23. Members of this family are zinc metallopeptidases with a range of specificities.
Therefore, EntL is a metalloendopetidase which can kill a wide range of Gram
positive bacteria including lactococci. (Hickey, Twomey et al. 2003).
The N-terminus of EntL is homologous to the catalytic domains of different
cell wall-degrading proteins with modular structures. These include lysostaphin,
ALE-1, zoocin A, and LytM, which are all endopeptidases belonging to the M37
protease family. This N-terminal domain is linked by a threonine-proline-rich region
to a putative C-terminal recognition domain, which shows significant sequence
identity to two bacteriophage lysins (Nilsen, Nes et al. 2003). No common
denominator has been identified in the interpeptide bridges in the peptidoglycan
chains of bacteria sensitive to EntL. However, all the sensitive bacteria have the L26

Ala-D-Glu-L-Lys-D-Ala stem peptide sequence in their peptidoglycan. This
suggests that it is most likely that EntL exerts its activity by hydrolyzing a peptide
bond in the stem peptide, suggesting that its activity is similar to that of millericin B
(Nilsen, Nes et al. 2003)

1.6.

Macromolecular analysis of lytic proteins

Protein crystallography is the major structural biology technique which
accounts for approximately 80% of all elucidated protein structures.(King, Chen et al.
2009). Combining three-dimensional structural information with whole genome
sequences have well-documented benefits due to the enormous success of
investigator

initiated,

h^^pothesis-driven

biomedical

research

using

X-ray

crystallography and NMR spectroscopy. (Burley 2000). X-ray crystallography is
essentially a form of very high resolution microscopy which enables the visualisation
of protein structures at the atomic level. This can enhance our understanding of
protein function, but also how proteins interact with other molecules, undergo
conformational changes or catalyse reactions in the case of enzymes. The information
that emerges from this analysis can be used to design novel drugs that target a
particular protein, or to rationally engineer an enzyme for a specific industrial
purpose. Dorothy Crowfoot Hodgkin and her mentor J.D. Bernal were the first to
successfully apply x-ray diffraction to crystals of biological substances. In 1934, they
first applied this science to Pepsin and went on then to solve the structure of
cholesterol (1937), Vitamin B12 (1945), Penicillin (1954) and Insulin (1969).
Hodgkins was awarded the Nobel Prize in chemistry in 1964 for her solved structure
of penicillin.
In order to see proteins in atomic detail. X-rays, with a wavelength of around
0.1 nm or 1 A, are diffracted by the electrons in the structure of interest. The X-ray
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diffraction pattern that emerges is recorded using an image plate or charge-coupled
device (CCD). The diffraction from a single molecule would be too weak to be
measurable; therefore, ordered 3-dimensional arrays of molecules, or crystals, are
used to magnify the signal. The result is a 3-dimensional map showing the
distribution of electrons in the structure.
The steps involved in the determination of a crystal structure are protein
preparation, crystallization, testing crystals. X-ray data collection, structure solution,
model building and refinement. Each step in discussed in more detail below.

1.6.1. Protein Purification
Protein purification is the first step in the protein ciy^stallization process. High
quality purified protein can be critical in respect of protein activity and crystallization
ability. Several rounds of purification must first be performed in order to achieve a
protein of at least 97% purity before crystallization screens can be performed. The
protein should be pure and homogeneous, soluble and folded, active and stable. If the
protein sample fails one or more of these criteria, it is often worthwhile returning to
the expression and purification protocols used.
1.6.2.

Crystallization and Testing Crystals
Once a protein has been purified to 97% purity and has satisfied the criteria as

outlined above, crystallization trials are performed. This involves using protein at an
optimal concentration, which for most soluble proteins is usually lOmg/ml to
15mg/ml (Falini, Fennani et al. 2002) in a sample buffer that promotes sample
stability, homogeneity and monodispersity. Screening employs vapour diffusion
methods such as hanging drop (Fig 1.10), sandwich drop and sitting drop to screen a
large number of buffers until conditions are ideal to induce protein crystal growth. All
of these methods employ vapour diffusion which is the most commonly utilized
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technique for protein crystallization (Saridakis and Chayen 2000). The rate of water
evaporation is of monumental im.portance to the quality of crystals.(Martins, Rocha et
al. 2008). Once a crystallization reagent has produced a form of crystal, microcrystal,
or crystalline precipitate, this set of reagents will be used as a starting point to
optimize grid screens. Additives and detergents can be added to the screens in order
to increase the likelihood for crystallization or to improve crystals. Other variables
which can be introduced are temperature, pH, precipitation, concentration etc
(Wiencek 1999). Upon successful protein crystallization, the crystal must be tested to
ensure it is an organic protein crystal. The most definitive test in this case is to obtain
an x-ray diffraction pattern of the crystal.
Another method used to test protein cr>'stals is dehydration (Newman 2006).
A biological crystal typically has very significant solvent content and will dehydrate
when removed from the drop or the drop is allowed to evaporate from around the
crystal. Bifringence is another mechanism that can be used to test a protein crystal.
Biological crystals are typically weakly birefringent under cross polarizers (Inoue and
Goda 2001). A biological crystal has large solvent channels which can absorb small
molecule dyes such as Izit (HR4-710) by Hampton research.
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Figure 1.10 : Vapour diffusion hanging drop,

1.6.3. X-ray data Collection
X-ray data collection is a central part of all protein crystallography. Once
crystals have been generated. X-ray data is collected and diffraction is observed. The
crystals are first mounted onto a cryo-loop and flash cooled to lOOK. The loop is then
attached to a goniometer head which allows the sample to be accurately positioned in
the X-ray beam. For cryogenic data collection, a cold stream of nitrogen gas is passed
over the crystal in order to keep the crystal at 100 K throughout the experiment.
Focused X-rays emerge from a collimator and strike the crystal to produce a
diffraction pattern. Ideally the crystal should diffract to 4 A or more. In the event that
a diffracted crystal is generated, cryoprotectants need to be tested in order to protect
the crystal from the low temperatures of the cryostream (McGeehan, Ravelli et al.
2009). Once this information is obtained, the crystals can be frozen under liquid
nitrogen and stored in dewers until required for analysis at a synchrotron. A
synchrotron produces intense beams of x-rays, infrared and ultraviolet light called
synchrotron light. Once the x-ray hits the crystal it should create a diffraction pattern
which then needs to be elucidated (Hasnain, Helliwell et al. 1994).
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1,6.4. Structure Solution
In recent years, multiple anomalous replacement (MAD) has become the
method of choice used to solve macromolecular structures. The increase in
availability of synchotron beamlines equipped with low band optics, fast readout
detectors, user friendly interfaces and availability of new computer software which
locates the positions of the anomalous scattering atoms and calculates phases from
data has contributed to the popularity of this method. (Ealick 2000).A problem which
plagues crystallographers is the ‘phase’ problem. The single point on an area detector
or image plate does not reveal any phase information. In order to obtain a single peak
many points must be averaged and brought together in 3D to obtain a peak profile.
Each of these diffraction peaks does not contain any phase information.
There are several methods which crystallographers use to solve the phase
problem including direct methods, multiple of single isomorphous replacement
(MIR/SIR), multiple or single anomalous replacement (MAD/SAD) or molecular
replacement (MR). Small structures of approximately 1000 atoms are usually solved
by direct methods though larger structures can also be solved by direct methods as
long as high resolution data of ~1.1 A is procurable. MIR and SIR are utilized by
performing heavy atom soaking of macromolecular crystals. (Murray, Rudino-Pinera
et al. 2005). Diffraction data from non-derivatized crystals and from derivatives are
compared and the positions of the heavy atoms are derived from Patterson maps.
Using the position of the heavy atoms, the phases can be elucidated from the
differences in the intensities of the diffraction peaks from the native and derivative
datasets. MAD has to be performed on a synchrotron. MAD and SAD depend upon
scatterers being present in the structure. This method takes into account the fact that
anomalous scatterers can be located in the structure using Patterson maps. Knowing
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the positions of these scatterers, their contributions to the intensities of the peaks can
be calculated. (McCoy, Grosse-Kunstleve et al. 2007). Phase information can be
deduced from these contributions, by applying an iterative process. The MAD method
does present some distinct advantages over the MIR method; in particular problems
which arise from lack of isomorphism in MIR do not apply to MAD as data is
collected from a single crystal. (Ramin, Shepard et al. 1999). MR uses previously
elucidated structures as an incomplete model to solve the phase problem. However,
this method will only work if there is a proportionate amount of similarity between
the two structures.
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1.6.5.

Model Building and Refinement
Model building involves building a backbone and then amino acid side chains

into an electron density map. Many various tools and techniques are available for
electron density map interpretation. When high resolution data has been achieved,
there are several automated methods which can be applied here such as ARP/wARP
(Perrakis, Morris et al. 1999) , MAID (Levitt 2001), PHENIX AutoBuild Wizard
(Terwilliger, Grosse-Kunstleve et al. 2008) and Buccaneer(Cowton, McGivem et al.
2006). For low resolution data sets however, model building and refinement can be a
long manual process. The first step in model building is building the framework. This
is computed by averaging the position of each atom in the target sequence based on
the location of corresponding atoms on the template. If more than one template is
available the relative weight of each structure is determined by its homology with the
target sequence. Subsequently, loops must be defined. This can be done by
identifying similarities of loop regions in other known structures. The highest level of
error comes with defining the loop region in cases where there is low sequence
identity between the target sequence and the template. The backbone of the model is
completed by constructing a library based on pentapeptide backbone fragments from
the protein database (PDB). These are then fitted to overlapping Ca atoms of the
target model. Co-ordinates for a central tripeptide are then averaged to determine the
backbone atom (C, N, O). Lastly, side chains are added to the model. This will
generally depend on the sequence identity between the target sequence and the
template.
A table of most probable rotamers for each side chain and is then analysed to
see if they are acceptable by Van der Waals exclusion test. The favoured rotamers are
then added to the model. The model can be refined now by adjusting the atomic
model to improve its agreement with the measured diffraction data. There are several
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refinement proGrammes which have been used with success including Hendrickson
and Konnert restrained least squares program PROLSQ(Hendrickson 1985) and
another commonly used method of refinement is TNT, a programme similar to but
faster than PROLSQ which uses fast Fourier transform. It was created by Ten Eyck
and later refined by Tronrud (Tronrud 1992).

1.7

Conclusions
The emergence and dissemination of antibiotic resistant pathogenic bacteria

such as MRSA and VRE has been an increasing serious problem in the public health
worldwide. Resistant Gram-positive bacteria pose one of the most important
challenges to the infectious disease comimunity.(Bush 1997) EARSS is reporting that
Ireland has the third highest rate of MRSA and the highest incidence of VRE in
Europe. Given how widespread VRE and MRSA are at the moment and the lack of
effective antimicrobials, it is becoming necessary to explore alternative avenues in
order to obtain effective methods to combat them. LysK, a phage endolysin which
can be truncated to its CHAP domain has proven to be quite effective against MRSA
in past studies (Horgan et al, 2009). EntL, a bacteriocin secreted by some E. faecalis
strains can kill a wide range of Gram positive strains. Bacteriophages and small
antimicrobial peptides, whether of bacterial or eukaryotic origin, will more likely
become available in the treatment of disease but considerable research efforts will
still be necessary to realize that possibility.
The objectives of this study were to exploit LysK, an endolysin from a
previously-characterised broad host-range anti staphylococcal bacteriophage K for the
biocontrol of multi-drug resistant Staphylococcus aureus and also Enterolysin A
(entL) - A cell wall-degrading bacteriocin from Enterococcus faecalis which kills a
wide range of Gram-positive bacteria; enterococci, pediococci, lactococci and
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lactobacilli. The project aims are as follows; Overproduction and purification for
recombinant LysK and EntlA to produce high concentrations of purified protein for
downstream applications. Obtain crystals of the proteins to determine 3D structure.
Determine secondary structure analysis using circular dichroism. Develop parameters
for crystallizing LysK and EntL.
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Chapter II

Materials and Methods
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2.1.

Bacterial Strains and Plasmids
Bacterial strains and plasmids used in this study are outlined in Table 2.1.

Staphylococcal strains were routinely grown at 37 °C in Brian Heart Infusion Broth
(BHI, Merck Diagnostics, Darmstadt, Germany). Strains of E. coli XLl Blue
containing pQE60 and pQE30 constructs were routinely grown at 37 °C in LB broth
(Merck Diagnostics, Darmstadt, Germany) containing 100 pg mf' ampicillin (SigmaAldrich, Ireland). Lactococcal strains were grown at 37 °C in Ml7 broth (Difco,
Laboratories, East Molesey, U.K ) containing glucose (0-5 % v/v). Recombinant
clones were induced in superbroth medium, which contained per litre 20g Bacto
Tryptone (Difco, Laboratories, East Molesey, U.K), lOg Yeast extract (Difco,
Laboratories, East Molesey, U.K) and 5g of Sodium chloride (Sigma-Aldrich,
Ireland) containing 200 pg mf’ ampicillin (Sigma-Aldrich, Ireland)
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Table 2.1: Bacterial strains and plasmids used in this study

Strain

Relevant Properties

Source and Reference

E. C0// XLI Blue

Cloning host

Stratagene

S. aureus DPC5645 Indicator strain, methicillin-resistai Moorepark Food Research Centi
Culture Collection
L.lactis IL1403

Chopin et ah, 1984

Indicator strain

Plasmids Used
PQE60

LysK

(Native

protein

(495a (Horgan, O'Flynn et al. 2009)

cloned into vector POE60
PQE60

Cl (Chap domain of LysK (165ai (Horgan, O'Flynn et al. 2009)
cloned into vector PQE60

PQE30

EntL (Native protein (316aa)) cion (Nigutova, Serencova et al. 200^
intovector PQE30
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2.2.

Protein Expression
For the purposes of production of LysK and Cl, overnight cultures of E. coli

XLl Blue containing LysK and Cl constructs were inoculated (5%) into 10 ml of
Superbroth containing Amp 200 pg mf' and grown at 37 °C with aeration to an ODeoo
of 0.5 - 0.7. 1 ml of each culture was centrifuged, pelleted and resuspended in 50 pi
of Superbroth as a control. The remainder of each culture was induced with isopropyl
P-D-thiogalactopyranoside (IPTG, Sigma-Aldrich, Ireland) at a final concentration of
1 mM and incubated at 26 °C for 16 hrs with aeration. Following induction, cells
were centrifuged at 10,000 x g at 4 °C and cell pellets were resuspended in 5mls 10
mM Tris-HCl. Cells were lysed using a Sonicator (MSE Soniprep 150 - set at
frequency of 9-10) in 5 ml volumes for 2 mins with 5 secs on, 15 secs off on ice.
After sonication, the cells were centrifuged at 10,000 x g for 20 mins. The
supernatant was then used for subsequent analysis or frozen at -80 °C until required.
For induction of EntL, cells were grown as described above. In this case,
induction was performed with 1 mM IPTG for 3 h at 37 °C before harvesting the cells
by centrifugation and freezing the cell pellets at -80°C. Pellets were defrosted on ice
the following day. 2 mis of 25 mM Tris-FICl, 100 mM Sodium Chloride buffer was
added to each pellet.

Lysozyme was added at a final concentration of 1 mg/ml.

Protease cocktail (Sigma-Aldrich, Ireland) was added as per manufacturers’
guidelines of 1 ml per 100 mis. Following 30 mins incubation on ice, samples were
then sonicated (MSE Soniprep 150) for 6 x 10 secs on, 20 seconds off Following
centrifugation, the supernatant was frozen at -80 °C until required.
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2.3.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-Page gels were made up as follows; the 15 % resolving gel was made up

using 14 ml H2O, 15 ml 1.5 M Tris, 0.6 ml 10% SDS, 30 ml 30% acrylamide, 300 pi
10% APS and 30 pi of Temed. This was added to the gel casts and left to set. Once
set, the 4% stacking gel was poured over the resolving gel and allowed to set with a
12 well comb. The stacking gel consisted of 12.2 ml H2O, 5.0 ml Tris-HCl, 0.2 ml of
10% SDS, 2.6 ml 30% acrylamide, 100 pi of 10% APS and 20 pi Temed. Samples for
SDS-PAGE analysis were first mixed 4:1 with sample buffer (10% (v/v) glycerol,
62.5 mM Tris-HCL, pH 6.8, 2% SDS, 0.01 mg/ml bromophenol blue, 5% Pmercaptoethanol (BME)) and boiled for 5 mins. After boiling, 9 pi of each sample
was loaded into the wells and the gel was run using the Biorad apparatus at 200 V for
60 mins. A prestained SDS-PAGE broad range marker (Bio-Rad) was included to
allow size determination of protein bands. Following electrophoresis, the gels were
stained in methanol-acetic acid-water [40:10:50 (v/v/v)] containing Coomassie
brilliant blue (0.1% (w/v) Sigma-Aldrich) for 1 h - 2 hours at room temperature. The
gels were destained in methanol - acetic acid - water [40:10:50] for 1 hour to
overnight at room temperature.

2.4.

Zymogram analysis
Resolving and stacking gels were prepared as per SDS-PAGE procedure. 10

ml of autoclaved bacterial cells of interest were harvested by centrifugation at 10,000
X g for 20 mins. The supernatant was discarded and the pellet resuspended in 1 ml
H2O. This suspension was added to the resolving gel and let to set. Sample
preparation and electrophoresis conditions were as described above. Following
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electrophoresis, gels were incubated with renaturation buffer (2.5g% Triton X-100)
with agitation until a visible band of clearing could be seen (typically 1-2 hrs).

2.5.

Bradford spot test
Bradford reagent concentrate (Bio-Rad) was mixed 1;4 with MilliQ H2O. 10 pi

of each column fraction to be tested was mixed with 200 pi of the diluted Bradford
reagent in a multiwell microtitre plate. Samples which tested positive for presence of
protein turned blue.

2.6.

Ion exchange chromatography.
Ion exchange chromatography was employed for the initial purification of

LysK and Cl.

All of the chromatographic media were purchased from GE

Healthcare. 2-3mls of SP sepherose resin (GE healthcare) were pipetted into a 50 ml
sterile tube and washed x3 times with milliQ H2O. The sonicated supernatant sample
of LysK was centrifuged at 10,000xg for 20 minutes to remove any solids and 1%
glucose was added to the supernatant to prevent precipitation. The sample was then
applied to the prepared resin and allowed to rock at 4°C for 1-2 hours. The resin was
washed with 0.5M Na Acetate pH6.5 twice and then eluted with l.OM Na Acetate
pH6.5. Each wash step and eluate was analysed by SDS-PAGE.
Cl was purified using a chromatography column. 2-3mls of SP sepherose
resin (GE healthcare) were applied to the column (Econo-column chromatography
columns 737-1512). The resin was washed with 2 column volumes of milliQ H2O.
The sonicated supernatant sample of Cl was centrifuged at 10,000 x g for 20 mins to
remove any solids and was loaded onto the column at a rate of 0.5ml per min using
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the econopump (Biorad Econo Gradient Pump). The purification was performed over
a gradient of 20mM NaAcetate pH 5.5 and 0.5M NaAxetate pH 5.5. Fractions were
collected in 1 ml volumes. Fractions which tested positive for protein using the
Bradford spot test were further analysed using SDS-PAGE.
Pure fractions were pooled and exchanged into 50mM sodium acetate pH 6.5
using an Amicon ultra column (GE healthcare). Purified protein was stored at -80 C
until required.

2.7.

Ion Metal Affinity Chromatography.
A slurry of (2-3mls) chelating sepharose fast flow resin (GE healthcare) was

used to pack a column (econo-column chromatography columns 737-1512). The resin
was washed with 5 column volumes of milliQ H2O and subsequently treated with 1ml
of 0.2M Ni^+. The column was washed with 2 column volumes of milliQ H2O and 1
column volume of IX Phosphate Buffered Saline (PBS)
The sonicated supernatant sample of EntL was centrifuged at 10,000 x g for
20 mins to remove any solids and was loaded onto the column at a rate of 0.5ml per
min using the econopump (Biorad Econo Gradient Pump). The purification was
perfonned over a gradient of 20mM Imidizole and 0.5M Imidizole. Fractions were
collected in 1 ml volumes. Fractions which tested positive for protein using the
Bradford spot test were further analysed using SDS-PAGE.
Pure fractions were pooled and exchanged into 50mM NaAcetate pH 6.5
using an amicon ultra column device with a lOkDa nominal molecular weight cut-off
(Millipore). Purified protein was stored at -80° C until required.
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2.8.

Size exclusion chromatography using AKTA Fast Protein liquid

chromatography (FPLC) system (Amersham Biosciences).
To further purify the proteins the affinity or ion exchange purified proteins
were loaded on the size exclusion column Superdex 200 (Amersham Biosciences),
powered by an AKTA PrimePlus FPLC system (Amersham Biosciences). The
proteins of each peak were analyzed by SDS-PAGE. The FPLC was run using 50mM
NaAcetate pH 6.5.

2.9

Concentration and buffer exchange using Amicon Ultra.
Amdcon Ultra columns (Millipore) with 100 kDa molecular weight cut off

were initially washed using 2-3mls of buffer or deionized water and then repeated.
The sample was concentrated using Amicon ultra lOK filters at 4,000 x g for 30
minutes.
Protein samples were buffer exchanged into 50mM sodium acetate pH 6.5 using
Amicon ultra lOK filters at 4,000 x g for 60 minutes.

2.10

Preparation and quantification of protein stocks
Samples used in screening for crystals were the endolysin LysK (495aa), Cl

(165aa consisting of the CHAP domain) and the bacteriocin EntL (316aa). Protein
samples were prepared as described above.
The protein concentrations were determined spectrophotometrically using
extinction coefficients of 1.947 for LysK’ 2.442 for Cl and 2.065 for EntL.
Cl was stored at -80 °C in 50 mM Sodium acetate pH 6.5 buffer at a
concentration of 12mg/ml. LysK was stored at -80 °C in 50mM Sodium acetate pH
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6.5 buffer at a concentration of 1.8mg/ml. EntL was stored at -80 °C in 50mM
Sodium acetate pH 6.5 buffer at a concentration of 12mg/ml.

2.11

Secondary structure analysis of protein structure using JPRED
For secondary structure prediction, the amino acid sequences of LysK, Cl and

EntL respectively were input into Jpred (http://www.compbio.dundee.ac.uk/wwwjpred/).

2.12

CD data collection and processing
All protein preparations were desalted by Amicon Ultra desalting columns

(MW cut off - 10,000 Da; Millipore) or size-exclusion chromatography. CD spectra
were collected on a JASCO 700 spectropolarimeter using filtered protein solutions in
10 mM potassium phosphate buffer, pH 7.0, with concentrations of 0.02 mg ml * for
LysK, 0.067 mg mf* for Cl and 0.052 mg mf* for EntL in a 0.1 cm cell. Data were
collected from 190 to 260 nm. Data were expressed in terms of [^]MRW.

2.13

Thermal dcnaturation
Thermal denaturations using circular dichroism (CD) at 222 nm as a probe of

structure were performed using a Jasco700 spectropolarimeter equipped with a Peltier
thennocontrol unit. Proteins were exchanged into 10 mM potassium phosphate
buffer, pH 7.0, at concentrations of 0.02 mg mf* for LysK, 0.067 mg mf* for Cl and
0.052 mg ml'* for EntL in a 0.1 cm cell. Thermal ramps were performed from 20 to
80 °C in steps of 5 °C.
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2.14

Crystallization
Purified Cl (165aa) at various concentrations ranging from 6 mg mf^ to 20

mg mf^ were used to initiate crystal screening. Hampton Research Crystal Screens 1,
2 and Index 1 were used with drops consisting of 1 pi protein solution and 1 pi
crystallization buffer using vapour diffusion hanging-drop method. Plates were
incubated at room temperature and were analysed after 24 h, 48 h and one week.
Optimization of crystallization conditions involved designing customized screens to
vary conditions e.g. pH, precipitant, concentration and temperature.
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Chapter III

Results
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3.1

Purification of LysK

The lysK gene encoding the staphylococcal phage K endolysin, LysK (495aa),
was cloned into the pQE-60 expression system (Qiagen) (Fig. 3.1) by Horgan et al.
(2010). E. coli XL 1-Blue cells harbouring the resultant plasmid could be induced to
produce the LysK protein at 26 °C for 16 hrs using a final IPTG concentration of 1
mM (Fig 3.2).
As LysK produced from the pQE60 system contains a His - tag, purification
was initially performed using Immobilized metal ion affinity chromatography
(IMAC). LysK eluted from the IMAC column in trace amounts as seen in Fig 3.3
when samples were analysed by SDS-PAGE. In an attempt to improve the LysK
yield, the imidazole concentration of the elution buffer was increased from 0.5 M to
2.0 M imidazole and 2.0 M NaCl was also added. However, no improvement in the
yield of LysK from the IMAC column was observed.
Successful purification of LysK was carried out using a batch method of
purification employing ion exchange chromatography, using a block gradient of 1.0
M sodium acetate, pH6.5, followed by 1.5 M and 2.0 M sodium acetate, pH 6.5. (Fig.
3.4). 1.5 M sodium acetate pH 6.5 was found to be the most ideal elution buffer intense bands corresponding to LysK were seen on the SDS-PAGE gel, with the least
amount of contaminating bands as seen in fig. 3.4 lane 3.
Purified fractions were concentrated using an Amicon ultra column device
with a 10 kDa nominal molecular weight cut-off (Millipore) and were exchanged into
50 mM sodium acetate, pH 6.5, in order to avoid any precipitation. Further
purification of LysK samples was achieved by size exclusion chromatography using a
Sephadex 200 column by FPLC. Fractions positive for protein were further analysed
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by SDS-PAGE (Fig 3.5 B). These pooled fractions were also used for zymogram
analysis using MRS A strain DPC5645 as the substrate. As shown in Fig 3.5 A,
purified LysK is still active against MRSA strain DPC5645, indicating that the
purification process employed in our study did not affect the catalytic function of
LysK.
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Figure 3.1 pQE60 expression system from Qiagen used for heterologous expression of
LysK.
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7S,444
53.086

35.719

Figure 3.2 Direct detection of LysK by SDS-PAGE following IPTG induction for 16 hours
at 26 °C. Lane 1, Cell extract from E. coli XL 1-blue harbouring LysK, Lane 2: control, no
induction of LysK. , Lane 3, Standard molecular weight marker (Biorad).
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9
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M

78.444
53,086
35.719
28.329

19.325

Figure 3.3 Detection of LysK indicated by the arrow in IMAC fractions by SDS-PAGE
Lane 1- Lane 9, Cell extract from E. coli XLl-blue harbouring LysK , Lane 10, crude LysK
lysate, Lane M, Standard molecular weight marker (Biorad).

207.375
114,363
78.444

LysK

19,325

Figure 3.4 Detection of LysK in lEX fractions by SDS-PAGE. Lane 1 and 2 contain
fractions from lEX eluted with 1.0 M Sodium acetate pH 6.5, Lane 3 contains fractions from
lEX eluted with 1.5 M Sodium acetate pH 6.5, lane 4 contain fractions from lEX eluted with
1.0 M Sodium acetate pH 6.5 and Lane 5 contains crude lysK lysate. Lane M. Standard
molecular weight marker (Biorad).
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Figure 3.5 (A). Zymogram containing autoclaved MRSA (DPC5645) cells. LysK can be
seen lysing the autoclaved cells after purification by lEX and SEC. (B). Detection of LysK
on SDS-PAGE after purification by SEC using FPLC. Lanes 1-3 contain purified fractions
from the FPLC after elution with 50 mM sodium acetate pFI 6.5, Lane M denotes a broad
range SDS-PAGE marker (biorad).
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3.2

Purification of the native protein Lysk and the truncated Cl
Cl is a 165 amino acid fragment of LysK containing the first catalytic

domain, or CHAP (cysteine- and histidine-dependent amidohydrolase/peptidase)
domain only (18 kDa) This truncated version of LysK was cloned into the pQE60
expression system (Fig. 3.1) by Horgan et al. 2009. As for the full length LysK
protein, induction of the Cl protein was perfomied at 26 °C for 16 hours using a final
IPTG concentration of ImM (Fig 3.6). The Cl protein expressed from the construct
used was untagged and therefore lEX chromatography was employed for purification
purposes. Eluted fractions from lEX were tested using the Bradford spot test to
estimate total protein concentration. Each positive fraction was analysed by SDSPAGE (Fig; 3.7). It can be clearly seen from figures 3.4 and 3.6 that Cl was purified
in higher yields than the native protein LysK by lEX. 2 litres of induced LysK
resulted in a yield after purification of 1.8 mg/ml. By contrast, similar volumes of Cl
gave a much higher yield of 20 mg/ml.
Further purification of Cl was performed by size exclusion chromatography
using a Sephadex 200 column by FPLC. Fractions positive for protein were further
analysed by SDS-PAGE (Fig 3.8). Zymogram analysis using autoclaved cells of the
MRSA strain DPC5645 as the substrate showed Cl is active against MRSA in a
purified state. (Fig 3.9).
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Figure 3.6 Direct detection of Cl by SDS-PAGE after induction with IPTG for 16 hours at 26 "C.
Lane 1 SDS-PAGE analysis of Cl after extraction from E.coli XLl-blue cells, Lane 2 control where
Cl was not induced with IPTG after 4 hours., Lane 3 Standard molecular weight marker (Biorad).
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Figure 3.7 Detection of C1 in fractions from lEX on SDS-PAGE gel. Lane 1 - 22 contain fractions from lEX
eluted with 0.5 M Sodium acetate pH 6.5, Lane 13 contains flow through from the column and lane 14 contains
luipunfied C1. Lane M Standard molecular weight marker (Biorad).
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Figure 3.8 Detection of Cl on SDS-PAGE after purification by SEC using FPLC. Lanes 1-9
contain purified fractions from the FPLC after elution with 50 mM Sodium acetate pH 6.5, Lane M
denotes a broad range SDS-PAGE marker (Biorad).

.Cl (165aa) purified
by lEX&SEC

Figure 3.9 A zymogram containing autoclaved MRS A (DPC5645) cells. Cl can be seen lysing the
autoclaved cells after purification by lEX and SEC.

3,3

Purification of Enterolysin A

EntL(316aa, 35kDa) was cloned into the pQE60 expression system (Fig.3.1)
by(Horgan, O'Flynn et al. 2009). Induction of the protein was performed at 37 °C for
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3 hours using a final IPTG concentration of 1 mM (Fig 3.10). Since the EntL protein
is a His-tagged protein, IMAC purification was performed using the econopump
(Biorad Econo Gradient Pump) to collect fractions from the column. Fractions were
tested using the Bradford spot test. Each positive fraction was analysed by SDSPAGE (Fig. 3.11). As can be seen in Fig 3.11, the EntL protein in the IMAC
fractions were of high purity, and therefore, EntL was concentrated and used for
crystallization trials without further purification. Zymogram analysis using
autoclaved L. lactis IL1403 as the substrate showed EntL is active against the
lactococcal strain in its purified state. (Fig 3.12).

M
—-I jo7i?r♦—1 n4.>6j
<--- 1 75444

53.ce<!i

EntL

—I
—I
—j 19.3:^

6.973

Figure 3.10 Direct detection of EntL by SDS-PAGE after induction with IPTG for 3 hours
at 37 °C, Lane 1 IMAC purified EntL, Lane 2 EntL induced with ImM IPTG, Lane 3
control where EntL was not induced with IPTG after 1 hour. Lane M Standard molecular
weight marker (Biorad). Lane M donates a broad range SDS-PAGE marker (Biorad).
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Figure 3.1 Detection ofEntL in fractions from IMAC on SDS-PAGE gel. Lane 1- Lane 6 SDS-PAGE
analysis of EntL in fractions from IMAC, Lane M Standard molecular weight marker (Biorad).

(35kDi)
fjszf.td by I^LAC

Figure 3.12 A zymogram which contains autoclaved L.lactis (IL1403) cells. EntL can be seen lysing
the autoclaved cells after purification by IMAC.
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3,4

Secondary structure analysis of LysK, Cl and EntL
The nucleotide sequence of each protein was translated to a protein sequence

using Expasy Translate tool. This sequence was then input into the online secondary
structure prediction server JPRED (http://barton.ebi.ac.Uk/servers/jpred.h tml). The
JPRED server predicted the secondary structure for EntL, Cl and LysK as in Figures
3.13, 3.14 and 3.15, the results of which have been summarized in table 3.1.
Circular dichroism was performed and the observed ellipticities were
converted to mean residue ellipticity [0 MRW], by using the equation below.
[0MRW1= l0jobs(mrw)/lOc/
where 0 is the observed ellipticity in degrees; m.rw is the mean residue molecular
weight based on a molecular mass o; c is the protein concentration in Grams/ml, and /
is the path length of the cell in centimetres.
Once the units were converted to MRW, the data was input into K2D2
(http://WWW.ouic.ca/proiects/k2d2/). This software uses a self-organizing map (SOM)
algorithm, a type of neural network. Spectra from proteins with solved tertiarystructure are used as training sets to produce the SOM. From the resulting map of
spectra, "secondary structure maps" are derived.(Perez-Iratxeta and Andrade-Navarro
2008). K2D2 allows the percentage of secondary structures such as a - Helix and Psheets to be estimated. A comparison of secondary structure between the predicted
and the experimental was carried out. The results of this can be seen in Table 3.1 and
Table 3.2. The predicted and the experimental results are not entirely in agreement.
This could be because the experimental procedure using circular dichroism is more
accurate as it measures the change in absorbance in the far UV region. Where the
predicted and experimental data is in agreement is where both state that each lysin is
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predominantly composed of P-sheet and coil consisting in the least amount of a Helix.
Thermal denaturation was performed on each lysin after being exchanged into
10 mM Potassium Phosphate pH 7.0. Temperature ranged from 20-80 °C and
increased in increments of 5 °C. In Figures 3.16, 3.17 and 3.18 it can be seen that the
denaturation was irreversible in the case of EntL and C1. Upon cooling, no reversal in
the spectral features is observed. This indicates that the protein is susceptible to
temperature-induced denaturation.
The melting curve of each protein was detennined by monitoring [0] at 222
nm. The [0] 222 was recorded while heating the sample at the rate of 0.5 °C min (2080 °C). The transition temperature, Tm, was determined as a temperature indicative
of a midpoint between native-folded and completely-unfolded forms. Figures 3.19,
3.20 and 3.21 show absorbance at 222 nm plotted against circular dichroism in mDeg.
It can be seen clearly in each graph that no refolding takes place upon cooling for
both Cl and EntL. LysK however has partial refolding. Further analysis (table 3.4)
into the secondary structure of LysK was performed and it was found that upon
denaturation at 75°C, there was a signicificant loss of a - helix whilst only a
negligible loss in p-sheet. This would suggest that loss in secondary structure
accompanies LysK denaturation. Interestingly, it can be seen that upon cooling the
majority of the a-helix structure lost has been regained upon refolding. The Tms of
each lysin have been summarized in Table 3.3. The Tm for LysK is 45 °C whereas
for Cl, the Tm is 49-50°C.
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ASNEWSWPLGKPYAGRYEEGQQFGNTAFNRGGTYFHDGFDFGSAIYGNGSV
YAVHDGKILYAGWDPVGG

GSLGAFIVLQAGNTNVIYQEFSRNVGDIKVSTGQTVKKGQLIGKFTSSHLHLG
MTKKEWRSAHSSWNKD
HHHHH..........................

................

DGTWFNPIPILQGGSTPTPPNPGPKNFTTNVRYGLRVLGGSWLPEVTNFNNTN
DGFAGYPNRQHDMLYl
................................... HHHH.............................................

KVDKGQMKYRVHTAQSGWLPWVSKGDKSDTVNGAAGMPGQAIDGVQLNY
ITPKGEKLSQAYYRSQTTKR
..................................................

....... HHHHHH-------

SGWLKVSADNGSIPGLDSYAGIFGEPLDRLQIGISQSNPF
---------- HHH----

-----

Figure 3.13: Secondary structure prediction of enterolysin EntL as determined by JPRED. H = aHelix

p-sheet, - = disordered structure.
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GNRVYCPVRTCQGVPP
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Figure 3.14: Secondary structure prediction of endolysin LysK as determined by JPRED. H = aHelix,
P-sheet, - = disordered structure.

MAKTQAEINKRLDAYAKGTVDSPYRVKKATSYDPSFGVMEAGAIDADGYYH.
QCQDLITDYVLWLTDNK
—HHHHHUHHHHHM...........

.......................................

VRTWGNAKDQIKQSYGTGFKIHENKPSTVPKKGWIAVFTSGSYEQWGHIGIVY
GGNTSTFTILEQNWN
- -HHHHHHH.........

...........

.........

GYANKKPTKRVDNYYGLTHFIEIPVKA

Figure 3.15: Secondary structure prediction of endolysin Cl as determined by JPRED.
H = a- Helix,

P-sheet, - = disordered structure.

62

Secondary structure analysis of LysK, Cl and EntL
Secondary Structure (%)

Protein
LysK
a - Helix
13.1
^ - Sheet or extended 26.9
Coil
60.0

Cl
11.52
27.27
61.21

EntlA
5.2
25.1
69.7

Table 3.1: Prediction of % secondary structure using JPRED.

Secondary Structure Percentage %
Protein

LysK

a - helix

21.63%

Cl
1.76%

B- sheet

30.41%

47.42%

28.35%

Coil

47.96%

50.82%

60.12%

EntL
11.53%

Table 3.2: Experimental determination of secondary structure using circular dichroism data inserted
into K2D2. Secondary structure data calculated at 20°C, (http://www.ogic.ca/projects/k2d2/)
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Figure 3.16: Graph of the wavelength plotted against circular dichroism (mDeg) of EntL
(0.052mg/ml) in 10 mM Potassium Phosphate pH 7,0.
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Figure 3.17: Graph of the wavelength plotted against circular dichroism (mDeg) of
LysK (0.02mg/ml) in 2.5 mM Potassium Phosphate pH 7.0.
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Figure 3.18: Graph of the wavelength plotted against circular dichroism (mDeg) of Cl (0.067mg/ml)
in 2.5 mM Potassium Phosphate pH 7,0.

Melting Curve EntL

Figure 3.19: Thermal denaturation curves of EntL(0.052mg/ml) in lOmM potassium phosphate at pH
7.0 measured over absorbance of 190 - 300nm
The heating rate was 1.0°C:min.
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Melting Curve Cl

Figure 3.20:Thermal denaturation curves of Cl(0.067mg/ml) in lOmM potassium phosphate at pH 7.0
0 measured over absorbance of 190 - 260nm.
The heating rate was 1.0®C:min.

Melting Curve LysK

Figure 3.21: Thermal denaturation curve of LysK(0.02mg/ml) in lOmM potassium phosphate at pH
7.0 measured over absorbance of 190 - 260nm. Temperature was increased in increments of 5°C.The
heating rate was 1.0°C:min.
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Fig 3.25: Melting temperature of LysK at 220nm.
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Fig 3.26 Melting temperature of C1 at 222nm
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Fig 3.27: Melting temperature of EntL at 222nm

LysK

Protein

Melting Temperatun 45

Cl

EntL

49-50

55

No

No

(Tm °C)
Refolding?

Yes - Partial

Table 3.3: Tm and refolding capability of LysK, Cl and EntL.

Elements of
Structure
a - helix
B - sheet
Disordered
structure

20“C

37®C

45“C

75“C

45®C

37“C

20“C

17.36% 17.36% 20.63%
21.63% 21.63% 17.36% 9.65%
30.41% 30.41% 33.68% 38.75% 33.68% 33.68% 31.46%
47.96% 47.96% 48.96% 51.6% 48.96% 48.96% 47.91%

Table 3.4: Analysis of secondary structure of LysK under unfolded and refolded conditions as
deconvoluted from CD spectra.
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3.5

Crystallization
Initial screening for crystallization conditions for Cl was performed using the

Hampton Research screens - crystal screen 1, crystal screen2 and Index 1. For
screening, the vapour diffusion hanging drop method was employed. 1 pi of protein
of various concentrations were mixed on a cover slip with 1 pi of the crystallization
solution from the Hampton research crystal screens and was then inverted over the 24
plate hanging drop well using vacuum grease in order to seal the well off from
outside air.
Initially, crystalline precipitate was observed in condition X from crystal
screen 1, i.e. O.IM sodium cacodylate trihydrate pH 6.5, 1.4M sodium acetate
tnhydrate (Fig 3.24). Using this condition as a starting point, custom screens were
prepared varying the molarity, pH and other precipitants. From these screens,
improved crystals were grown. Crystals from a representative condition (2M
ammonium sulfate, 2% PEG 400, 0.1M cacodylate pH 7.5) growing as long needles
are shown in Fig 3.24 B. The crystals were grown at room temperature at a
concentration of 12 mg/ml at a ratio of 1 pi protein solution to 1 pi of mother liquor.
Tie crystals grew within days and continued growing for approximately 1 -2 months.
To confirm these crystals as protein, they were tested with Izit dye (Hampton
research). Izit is a small molecule dye which works by filling solvent channels in the
protein crystals. By contrast, salt crystals would not have these solvent channels. 1 pi
o:' Izit was placed into the crystal drop. After an hour of incubation, the crystal turned
bue indicating a positive result and the likelihood of the crystal to be a protein crystal
(lig 3.25). The crystals were also checked under a set of polarized lens for
brefringence - which is the term applied to materials which reflect light in a manner
ttat depends on its state of polarization. Protein crystals are weakly birefringent (Fig
324 A, B and C).
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Fig 3.24: Polarized images of Cl crystals.(A) Polarized image of Cl crystallized in 0.1 M sodium
cacodylate trihydrate pH 7.5, 1.4M sodium acetate trihydrate, (B) Polarized image of C1 crystallized in
2M ammonium sulfate, 2% PEG 400, O.IM cacodylate pH 7.5, (C) Polarized image of Cl needle like
crystals. Crystallized in 2M ammonium sulfate, 2% PEG 400, O.IM cacodylate pH 7.5

LysK was purified and concentrated to approximately 1.8mg/ml. Using this as
a starting point crystal screens were performed using Hampton research screens crystal screen 1 and crystal screen 2. Amorphous precipitation was observed in 75%
of the conditions indicating the concentration was too high for crystallization. The
concentration was lowered to 1 mg/ml however; no crystals have been noted to date.
EntL underwent screening using Hampton screens - crystal screen 1, crystal
screen 2, Index 1 and Index 2 using an initial protein concentration of approximately
12 mg/ml. Again precipitation was noticed in 75% of the conditions so the
concentration was lowered to 6mg/ml and no crystals have been observed to date.
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3.6

Cryoprotectant screening Cl
After successful crystallization of Cl, suitable cryoprotectants were screened.

A suitable cryoprotectant is one which stabilizes the crystal and protects it from the
cryogenic stream on the x-ray diffractometer whilst combining with the
crystallization reagent to fonn an amorphous glass. Each cryoprotectant was screened
using an x-ray diffractometer (Generator Rigaku MicroMax-007, Raxis IV^
Detectors, Philips x-stream Cryostream). A cryopin, which is small microscopic loop,
was used to take a loop of prepared cryoprotectant. This is flash frozen under a stream
of nitrogen gas. Visibly, an ideal cryoprotectant should freeze as a clear glass (Fig.
3.25 A) and be free of ice-rings in the diffraction image.
57 cryoprotectants were tested under the cryo stream. Those that froze as a
clear glass are summarized in Table 3.4. Only two of these cryoprotectants were
suitable for the Cl crystals - 0. IM Cacodylate 7.5, 2M Ammonium Sulfate, 2%
PEG400, 26% glycerol and 2.9M LiCl O.IM Cacodylate 7.5, 2M Ammonium Sulfate,
2% PEG 400. These conditions provide a clear glass which did not form ice rings in
the diffraction image and furthermore the crystals appeared to be stable during
handling in these conditions prior to mounting.
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Original Condition

Condition

Cryoprotectant Score

5% Peg, 0.2M HEPES, 40% PEG 400, 0.2M HEPES pH 7.5, PEG 400
0.2M CaCb

Clear

0.2M Cacl2

10% Peg, 0.2M HEPES 10% PEG 400, 0.2M HEPES pH 7.5, 70% Sucrose
0.2M CaCb

0.2M Cacl2, 40% Sucrose

1.4M Sodium acetate,

30% PEG 400, 1.4M Sodium acetate PEG 400

Clear

Clear

O.IM Sodium cacodyl at 0. IM Sodium cacodylate pH 6.0
pH 6.0

40% PEG 400, 1.4M Sodium acetate PEG 400

Clear

0. IM Sodium cacodylate pH 6.0
2M Ammonium sulfate. 26% Glycerol, 0. IM Cacodylate 7.5, PEG 400

Clear

2% PEG 400, O.IM

2M Ammonium Sulfate, 2% PEG 40'

cacodylate pH7.5.

2.9M LiCl, O.IM Cacodylate pH7.5, Lithium Chloride Clear
2M Ammonium Sulfate, 2% PEG 40'

Table 3.4: Cryoprotectants which froze as a clear glass

3.7

Crystal freezing.
A cryo loop is used as a holder for the crystal. Crystals were removed from

their mother liquor with a nylon loop and transferred to a cryoprotectant solution
consisting of
The crystal was transferred immediately to a second solution of cryoprotectant before
being frozen in liquid nitrogen.
Once the crystal was picked up from the cover slip, it was then transferred to
cryoprotectant solution and picked up again and transferred to another cryoprotectant
solution in order to wash off any mother liquor which might cause ice rings upon
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freezing and cause disruption to diffraction data. Directly after the second wash in
cryoprotectant solution, the crystal was plunged directly into liquid nitrogen The
crystal was placed in the storage tube under liquid nitrogen and stored in aluminium
canes in cryo dewars. The Cl crystals were stored in cryo dewers as per table 3.5 and
are awaiting analysis at the Diamond synchrotron (South Oxfordshire).

3.1

3.2

3.3

2M Am sulphate, 2 2M Am sulphate, 2% 2M Am sulphate, 2%
PEG 400, Cacodyh PEG 400, Cacoylate

3.5

2M Am sulphate, 2®/<

PEG 400, Cacodylate PEG, Cacodylate

pH 7.5

pH 7.5

pH 7.5

pH 7.5

Fragment of long

Fragment of long

Small Needle

Small crystal

needles 20micron x needles

Location - Top of Loc

lOOmicron

Location - Top of Lo( Cryo - LiCl

Location - Top of

Cryo - Li Cl

Loop

Table 3.5 Crystals as frozen in dewar
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Chapter IV

Discussion and Conclusions
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4.1

Discussion
During the course of this study, a number of phage- and bacteria-derived

proteins, with potential to be used as alternatives to antibiotics, were purified and
efforts were made to obtain structural information by X-ray crystallography.
Interest in phage lytic enzymes has increased in recent years as potential
alternatives to antibiotics, which are becoming less effective due to the increase in
antibiotic resistant pathogens. Lysins have the ability to rapidly lyse bacterial strains
for which they have high specificity. An important advantage of lysins is that they,
unlike broad spectrum antibiotics, only kill the pathogen of interest. In cases where a
broader spectrum antimicrobial is needed there is potential for the construction of
chimeric enzymes - combining the catalytic region of one lysin to the catalytic
domain of another. The potential for phage lysins at present is very exciting.
Bacteriocins are antimicrobial agents produced by bacteria which inhibit the growth
of closely related strains Bacteriocins are important in the food industry to prolong
the shelf life of food as natural preservatives. Nisin is one such bacteriocin being used
to date as a safe food preservative in over 50 countries. (Delves-Broughton,
Blackburn et al. 1996).
X-ray crystallography is the study of crystal structures through X-ray
diffraction techniques. The determination of a novel protein structure by X-ray
crystallographic analysis involves a number of fundamental steps, the first of which is
protein purification. Highly purified and concentrated protein is very important in Xray crystallography studies. Any contaminants within the protein solution can have
adverse effects on the outcome of crystallization studies. Large quantities of purified
protein must be available - large, single protein crystals which diffract must be grown
and diffraction information must then be analysed. Previous antimicrobial proteins
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which have been crystallized include the bacteriophage PSA Endolysin (Korndorfer,
Danzer et al. 2006). The elucidation of the crystal structure of PSA revealed a fold
within the protein responsible for Listeria cell wall recognition. This cell wall binding
mechanism is responsible for the specificity of the endolysin. Another structure
which has been recently solved is that of the modular endolysin from Phage Cp-l
(Hermoso, Monterroso et al. 2003). The peptidoglycan binding site was found to be
on the C-terminal end of the catalytic domain.
LysK and EntL are noteworthy antimicrobial peptides that have been
investigated during this study. The phage endolysin, LysK, displays potent
antibacterial activity against bovine and human staphylococcal strains including
MRSA.(O'Flaherty, Coffey et al. 2005) The bacteriocin-like EntL inhibits growth of
enterococci, pediococci, lactococci and lactobacilli. (Nilsen, Nes et al. 2003). In the
course of this work, both LysK along with its truncated CHAP domain (designated
Cl in this thesis) were successfully purified by employing various chromatographic
techniques.

Both purified LysK and Cl behaved as homogeneous proteins when

purified and analysed on SDS-PAGE after purification and activity of the purified
proteins against MRSA was evident from zymogram analysis. LysK purification has
also been described by Becker et al (Becker, Dong et al. 2009) where successful NiNTA nickel chromatography was performed. The purified LysK protein used in the
Becker study was produced from induction of the lysK gene cloned into the pET-21a
expression vector. Initial attempts at purification in our study also used Ni-NTA
nickel chromatography. However, as discussed previously, problems arose with this
system and purification was unsuccessful. We hypothesize that perhaps the His-tag,
attached to the LysK protein when expressed from pQE60, was embedded within the
protein, resulting in difficulties in detachment from the column in quantities required
for crystallography studies.

A batch method of purification using ion exchange
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chromatography was attempted. In this case, the protein had to be incubated with the
SP sepharose resin before elution. As the Becker study were successful in purifying
LysK using an IMAC method one can assume this is because of the difference in
expression vectors being used. The Becker study used a C-terminal 6x his-tagged
LysK cloned into vector p-ET21a where an additional two amino acids (Leu-Glu)
were added at the C-terminus of the tagged LysK corresponding to the Xhol site. This
study performed purification using a C-terminal 6x his-tag LysK cloned into vector
pQE60. It is possible that the additional amino acids used in the Becker study could
have an effect upon purification rendering the protein more or less agreeable to NiNTA purification. However further study would have to be done to prove this.
In a study by Horgan et al, in 2009, it was shown that crude Cl, a truncated
LysK protein containing the CHAP domain only, retains full lytic activity against
both dead and live staphylococcal cells including MRSA. The study compared the
activity of the native protein, LysK, with the activity of the truncated Cl against live
clinical staphylococcal cells. Interestingly, the CHAP domain on its own displayed
activity two-fold higher than LysK indicating the CHAP domain is more active
against staphylococcal cells than the native protein. Zymogram analysis conducted in
this study with purified protein correlates with these findings. Cl gives a much larger
band of clearing on the zymogram than LysK when loaded onto gels at the same
concentration. A similar result was seen by (Low, Yang et al. 2005) when they found
the N-terminal catalytic domain of the lysin PlyL is more active than the native
protein against B. subtilis, B. megaterium and B. anthracis cells. The Cl derivative
of LysK does not contain the SH3b cell wall-binding domain found in the full length
LysK protein. One possible explanation for how the truncated lysin recognizes
peptidolglycan in the absence of the cell wall-binding domain is that the CHAP
domain also plays a role in substrate recognition, along with its catalytic role. It may
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be possible that like Cpl-l(Hermoso, Monterroso et al. 2003), Cl may contain a
peptidoglycan binding site within the CHAP domain, thus explaining how this LysK
derivative retains the ability to lyse live cells. There are other cases where truncated
lysins maintain their lytic activity such as (Low, Yang et al. 2005) as mentioned
previously and also by (Morita, Tanji et al. 2001) who report enzymatic activity after
C-terminal deletion of a Bacillus amyloliquefaciens phage endolysin, however, there
was a loss in antibacterial activity.
EntL, a bacteriolytic compound produced by Enterococcus faecalis strain
DPC5280, was also purified. IMAC was the purification procedure of choice for
EntL, since the EntL protein is His-tagged. IMAC would be a standard purification
method for His-tagged proteins, as the metal (in our case 0.2M Nickel) binds to the
His-tag which will then elute when a high concentration of imidazole is applied to the
column. A purification scheme similar to that used by (Nigutova, Serencova et al.
2008) was employed, with some modifications as described in previous sections. The
methods employed led to biologically active EntL.
Following purification, the secondary structure of LysK, Cl and EntlL were
analysed theoretically and experimentally. Theoretically, secondary structure
predictions were made by inputting the amino acid sequence of each protein into the
online server JPRED which is an interactive protein secondary structure prediction
server. Circular dichroism is the experimental procedure used to analyze the
secondary structure of each protein. Circular Dichroism spectra were measured in the
far-UV and near-UV regions. For each protein, the experimental and the predicted
secondary structure results were collected and compared. In all cases, the
theoretically predicted and experimental results differed. It is not unusual for the
experimental data to differ from data generated by a prediction server such as JPRED.
JPRED predicts secondary structure based on a database of known structures. By
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contrast, the experimental analysis by circular dichroism calculates secondary
structure by inputting the CD data in units of delta epsilon into K2D2 K2D2 is a
method to estimate protein secondary structure from circular dichroism spectra. It
uses a self-organized map of spectra from proteins with known structure to deduce
maps of protein secondary structure that are used to do the predictions. Each unit
corresponds to protein secondary structure for example a-helix have negative bands at
222nm and positive bands are 193nm, P-sheets have negative bands at 218nm and
positive bands at 195nm coils then have negative values at both 210nm and 195nm
(Greenfield 2006) As the LysK structure is unknown and no structure to date has
been solved with high homology to the CHAP domain, it is not surprising that the
experimental data would differ to JPRED.

JPRED automatically searches for

homologues when a sequence is inputted into the online server, it then proceeds to
build multiple sequence alignments in order to come up with a secondary structure
prediction. According to the CD data, LysK is predominantly composed of p-sheet
and coil consisting in the least amount of a - Helix. Thus, whilst not in complete
agreement, the theoretical and experimental analysis of LysK performed in this study
point to LysK being predominantly composed of p-sheet. These findings do not
correlate with the recent findings by (Filatova, Becker et al. 2010), who found LysK
to consist predominantly of a - Helix by CD. Possible explanations for this could be
again due to the additional amino acids used in the Becker study rendering the protein
less stable and also difference in buffers used to perform the CD experiments which
will be explained in further detail below.
In addition, thermal denaturation was performed on all three proteins. In the
case of Cl and EntL, irreversible denaturation was seen as neither EntL nor Cl
proceeded to refold after denaturation.

LysK could be denatured by raising the

temperature up to 80°C and was partially renatured by lowering the temperature back
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to 20°C. Partial refolding has also been seen for placenta and heart laminin isoforms
(Lindblom, Marsh et al. 1994) and also laminin-5 - a specific component of basement
membranes underlying stratified epithelia (Rousselle, Golbik et al. 1995). One study
performed on a salmon cold active goose type lysozyme however, did show some
activity after being thermally denatured and renatured by differential scanning
calorimetry which would indicate some refolding. (Hermoso, Monterroso et al.
2003)As LysK refolded and the truncated Cl did not, it can be speculated that
without the cell wall-binding and amidase domains. Cl is more susceptible to heat
denaturation. Filatova et al have also performed a study monitoring the effects of
temperature denaturation on LysK. In that case, minor changes m P-sheet when
heated to 45°C were obseiv^ed, but a quite substantial loss of a-helix was noted. These
findings concur with our study, however on raising the temperature to 75°C, a
dramatic loss of a-helix was observed in this study. The loss of a-helical structure
observed for LysK is compensated largely by an increase in “other” (random coil)
structure and p sheet. Upon cooling back to 20°°C we found that the a-helix content
of LysK almost fully renatured. This confirms that LysK folding and refolding is
accompanied by changes in secondary structure and would suggest that LysK consists
of stable p-sheet secondary structure. What is interesting about the Filatova study is
that after incubation at 37 °C, aggregation in the SDS-PAGE gel after 24 hours
incubation was observed and subsequent variation on incubation times did not resolve
this. This aggregation seems to suggest irreversible folding whereas this study shows
that refolding is possible at least partially for LysK. One reason for this could be the
stability of the enzyme under different conditions, e.g. different buffers were used in
each study. An important part of any strategy to develop LysK as an antimicrobial
agent would be to optimize conditions of LysK storage and application so as to avoid
enzyme denaturation. Filatova et al, performed CD in a 20mM Tris 20mM potassium
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phosphate pH7.5 buffer. While performing initial CD scans in this study to determine
a suitable buffer which would give minimal interference below 200nm it was found
that 20mM potassium phosphate pH7.5 displayed very erratic behaviour below the
200nm region. Because of this an optimal buffer of 2.5mM Potassium phosphate pH
7.0 was employed for CD experiments in this study. The higher concentration
potassium phosphate buffer used by Filatova et al could account for the difference
seen between the two studies.
The thermal stability of LysK, EntL and Cl was further assessed by
monitoring the CD signal at 220 nm (LysK), and 222 nm (Cl and EntL) which are
primarily associated with helical structure. I’he initial loss of helical structure for each
protein started at a temperature over 50 °C. The Tm (the temperature at the m.idpoint
of the transition from the folded to the unfolded state) was calculated by plotting
circular dichroism (mDeg) against temperature at 220 nm for LysK. 220 nm was
chosen for LysK as at this wavelength, a large difference exists between the ellipticity
of the native and denatured states. Other studies which have calculated Tm at 220 nm
include (Vanderheeren and Hanssens 1994) and (Stillman and Somero 2001). High
melting points and the ability of a protein to refold are properties which increase shelf
life. However, as many proteins will precipitate almost immediately after they are
refolded making them irreversibly denatured, finding solvent conditions which
reverse the unfolding might be more important for shelf life than a high melting
temperature. Therefore, whilst EntL and Cl have a higher Tm than LysK, LysK has
the capacity to refold, indicating it would have a longer shelf life than Cl and
potentially more useful in the drug design process.
The Cl protein, which contains the catalytic CHAP domain (165aa) of LysK,
was successfully crystallized in 2 M ammonium sulfate, 2% PEG 400, 0.1 M
cacodylate pH 7.5. The morphology of the crystals were found to be long needles
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which took a few days to begin to grow and continued growing for a period of up to 2
months. Initial diffraction tests on small crystals gave very weak diffraction patterns
but were consistent with the crystals being of a proteinaceous nature. Four crystals
were successfully harvested and stored in a cryo dewar awaiting analysis at the
Diamond synchrotron (South Oxfordshire). A protein basic local alignment search
tool (BLAST) on the PDB database of Cl returned a structure “1R77_A” of the cell
wall targeting domain of peptidoglycan Hydrolase ALE-1 from Staphylococcus
capitis. ALE-1 is a novel staphylolytic enzyme which is active against S. aureus.
(Sugai, Fujiwara et al. 1997). ALE-1 shares high homology with LysK. Crystals of
the ALE-1 targeting domain were grown in 10 mM phosphate buffer, pH 6.2 mixed
with 4 u] of reservoir solution - 100 mM sodium acetate, 32-35% PEG 3350, and
lOOmM MES pH6.5 at a concentration of 12mg/ml (Lu, Fujiwara et al. 2006).
Interestingly, Cl was crystallized with 2% PEG 400 indicating that perhaps PEG
solutions are useful in crystallizing staphylococcal derived lysins. The ALE-1targeting domain consists of eight p-strands and two anti-parallel multiple-stranded psheets pack. The targeting domain has been classified as SH3b. SH3b domains are
modular proteins that mediate protein-protein interactions in signal transduction
cascades and membrane-cytoskeleton structures through recognition of proline-rich
ligands. The surface of SH3b domains consist of a hydrophobic region which
accommodates the special conformation of the proline-rich substrate.(Lu, Fujiwara et
al. 2006)
A BLAST was performed in the PDB database to determine whether any
crystal structures showing homology to EntL had been solved. The BLAST returned a
structure belonging to a putative lysostaphin peptidase from Vibrio cholera POL The
sequence of EntL only shares 32% identity with the peptidase sequence.
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Crystals of the peptidase were grown at room temperature in O.IM Tris pH
8.5, 25% PEG4000 and 0.2M ammonium sulphate. (Hermoso, Monterroso et al.
2003). The crystals diffracted to 1.9-A°. POl consists of 3 domains. Domains 1 and II
consist of a similar structure of five-stranded anti-parallel b-sheet with a pair of ahelices projecting from one face. A small p-strand followed by random coil joins
domains II and III. Domain III consists of 11 antiparallel P-strands.

4.1

Conclusions and Future Perspectives
This study involved investigation into procedures to purify and to establish

crystallization parameters for the bacteriophage endolysin LysK, a truncated LysK
containing only the CHAP domain (Cl) and the bacteriocin EntL. All three proteins
underwent studies in order to establish parameters for crystallization and parameters
were successfully determined for Cl consisting of the catalytic CHAP domain of
LysK. The crystals took between a few days to 2 months to grow. Initial tests showed
weak diffraction consistent with protein crystals. Circular dichroism studies
determined each protein is predominantly composed of p-sheet and coil consisting in
the least amount of a - Helix and also partial refolding of LysK occurred but not of
Cl indicating that the cell wall binding domain or the amidase domain or both are
required for thermal stability.
Pathogenic bacteria are quickly evolving and mutating to evade the
antimicrobial action of antibiotics. There is a current renewed interest in
bacteriophage therapy in Western Europe and the USA in light of the emergence of
drug-resistant pathogenic bacteria and there are strong indications that phages may
yet have an important role to play in the treatment of bacterial infection in western
countries. Phage technologies and products are certain to gain a foothold in clinical
applications, if only to compensate for the ever-increasing decline in the efficacy of
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antibiotics. In addition, there is still an untapped, immeasurable market for phage
applications in veterinary and agricultural settings. However, to date, there have been
very few rigorous and controlled studies on any phage bacterial system in humans, or
indeed animals and some scepticism exists within the scientific and medical
communities. There will be many complex issues associated with using phage or
phage products to treat disease, principally the stringent and lengthy regulatory
processes required to go from promising molecule to drug on the market. While this
technology is still some way from commercialisation, there is a growing awareness in
Western Europe and the United States of the market potential of phage therapy and its
applications in the treatment of human infections, lb this end, a number of biotech
start-up companies have been formed to develop, manufacture, and achieve
regulatory approval of phage pharmaceutical products for the treatment of antibioticresistant and other bacterial infections. The possibilities for the future of phage, phage
lysins and bacteriocins are endless with an abundance of impressive applications
ranging from food preservatives to multidrug resistant therapy.
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